General MedicationsORALStandard
AKYNZEO
NETUPITANT; PALONOSETRON HYDROCHLORIDE
Standard Dose
300MG;EQ 0.5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview AKYNZEO is listed in Drugs@FDA under application 205718 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient NETUPITANT; PALONOSETRON HYDROCHLORIDE Form and strength CAPSULE;ORAL - 300MG;EQ 0.5MG BASE Sponsor HELSINN HLTHCARE Submission history Latest submission status date: 2021-06-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview AKYNZEO is listed in Drugs@FDA under application 205718 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient NETUPITANT; PALONOSETRON HYDROCHLORIDE Form and strength CAPSULE;ORAL - 300MG;EQ 0.5MG BASE Sponsor HELSINN HLTHCARE Submission history Latest submission status date: 2021-06-02 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.